Given the imbalance between pro- (IL-6 and TNF-α) and anti-inflammatory cytokines in CNO/CRMO, TNF-α blockers have proven useful in a subset of patients (up to 65%) [4,44,46]. The gene discussed is TNF; the disease is chronic recurrent multifocal osteomyelitis.